BD partners with Camtech Health to increase access to cervical cancer screening in Singapore

The first program in Japan that allows you to self-collect specimens for HPV testing at home

Singapore, February 21, 2024 /PRNewswire/ — BD (Becton Dickinson & Company) (NYSE:BDX), one of the world's leading medical technology companies, announced today that it is promoting cervical screening by launching a digital Announced strategic partnership with health company Camtech Health. By providing women with the first-ever option for cancer screening, Singapore Collect the sample yourself in the privacy of your home.

The program features the self-collection Camtech Health HPV (human papillomavirus) test and the BD Onclarity™ HPV Assay, a clinically validated test that can simultaneously detect 14 high-risk HPV strains (or “genotypes”). It's a combination. The purpose of this program is to improve cervical cancer screening uptake rates. Singaporefewer than half of eligible women are currently being tested.

“For women Singaporelack of time, embarrassment, fear, and inconvenience are the main barriers to screening.^Iand until now, Singapore “HPV testing was only available through hospitals or clinics that involved speculum examination and collection by a clinician,” he said. jeff andrews, BD's Vice President of Global Medical Affairs. “Cervical cancer is preventable, precancerous conditions are curable, and programs like this help support the national goal of eliminating cervical cancer. Self-collection protects your privacy at once. The ability to collect a sample in a preserved state not only makes HPV testing more accessible to women, but also allows them to be confident that the sample they collect is as reliable as one taken by a clinician.ⁱⁱ. ”

In late 2020, the World Health Organization (WHO) launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, recognizing the potential to virtually eliminate cervical cancer as a public health threat and I realized the possibility of eradicating cervical cancer in my lifetime.ⁱⁱⁱ. The strategy sets clear targets for HPV vaccination coverage (at least 90%), screening rates (at least 70%), and access to treatment (at least 90%) by 2030.

Home collection helps address the urgent public health challenge of reaching women who do not receive regular cervical cancer screening.

• Cervical cancer is the fourth most common cancer among women Globally, it is estimated that there will be 604,000 new infections and 342,000 deaths in 2020.^iv
• Almost all (over 95%) cervical cancers are caused by persistent HPV infectionis a very common virus transmitted through sexual contact.^I
• in SingaporeCervical cancer is the 10th most common cancer among women and the 4th most common cancer among women between the ages of 30 and 39.^v
• Cervical cancer screening for all women Singapore Ages 25-74 decreased by 17% between 2007 and 2019. From 58% to 48%.^V
• Among those aged 25 to 29, the decline was even steeper, from nearly 50% in 2007 to just 21% in 2019.^v

“Enabling self-collection at home is a first step to strengthening health and wellbeing, but making tests easier to use is equally important,” he said. Kuok Menghan, Chairman of Camtech Health. “The Camtech Health HPV test using the Camtech Health app is a simple process and ships in a prepaid package included with the kit. Samples are delivered using the BD Onclarity™ HPV Assay with fully automated integration. Analyzed using a model BD Viper™ LT using a molecular testing system and reviewed by a physician, the results are provided on the app and a virtual consultation is conducted to discuss any abnormalities.”

HPV is a large group of related viruses. Each virus within a group is given a number called an HPV genotype.^vii (or “type”). BD Onclarity™ is the only FDA-approved assay that independently tests for a wide range of HPV types, and specifically tests individually for three HPV types with a high risk of causing cervical cancer: HPV52 and HPV33/58. Masu. Singapore. Most clinically validated tests report multiple HPV types in a single combined result, which can mask the true risk of developing cervical cancer. The ability to identify high-risk genotypes prevalent in cervical cancer in a country is important for cervical cancer detection and prevention.

“Enabling women to self-test in the convenience of their homes will improve access to cervical cancer screening and empower women to take care of their health, especially in underserved communities. It's important to be able to manage it. Singapore “Who may be deterred from seeking medical care,” he said. Ida Ismail Pratt, a youth-led initiative dedicated to raising awareness about HPV and related cancers by working on effective strategies to ensure fair and affordable access to cervical cancer screening across the commonwealth. Advisor to the nonprofit Alliance for Affirmative Action Against HPV (A4HPV). “The proportion of women is less than 50%; Singapore For those undergoing regular cervical cancer screenings, it's reassuring that this self-sampling option is finally available. Singapore first time.I hope you find this additional option useful Singapore We aim to achieve the WHO cervical cancer screening target of 70% by 2030 and truly leave no one behind. ”

Combining HPV self-collection with assays that individually identify more types of HPV allows clinicians to risk stratify directly on screening samples without overtreating very low-risk women. , allowing us to focus on women who are most at risk.^VI. The BD Onclarity™ HPV Assay was the first in the industry to receive the CE mark for her HPV screening from self-collected vaginal samples at home.

Camtech Health is a digital health company focused on empowering people in various fields. Singapore and Southeast Asia To take control of your health and happiness and live a healthier, more fulfilling life. Camtech accomplishes this by integrating multiple disciplines and providing a seamless sample-to-insight testing experience with home self-collection testing kits. All from the convenience and comfort of your own home. For more information or to order Camtech Health HPV tests, visit www.camtech-health.com/health-tests or download the Camtech Health app (available on iOS and Android). Home self-collection kits are also available from SOG Health, a leading healthcare provider specializing in comprehensive health and wellness services for modern families. Singapore Provides obstetrics and gynecology services. https://www.sog.com.sg/about-sog/

About the BD Onclarity™ HPV Assay
BD Onclarity™ HPV Assay detects and identifies 14 high-risk human papillomaviruses (HPV) in a single analysis for cervical cancer screening purposes using both BD SurePath™ Preservation Solution and Hologic PreservCyt® Solution Provides genotyping information from specimens collected in Similar to cervical brush dilution tube (not approved in the US) US). This assay is intended for use as part of a comprehensive approach to cervical cancer screening, in accordance with clinical guidelines, and within local regulatory approval. The BD Onclarity™ HPV assay is FDA-approved for clinical use in cytology-based screening, co-testing paradigms, and primary HPV screening with ASC-US triage. This assay also meets international standards for HPV primary screening. The BD Onclarity™ HPV Assay is FDA-approved for use in vaccinated women. As previously vaccinated subpopulations age, women with reduced prevalence of HPV types 16 and 18 will gradually be included in the screening population, making it possible to This increases the value of extensive genotype reporting in a mixed population of untreated women. For more information, visit bd.com and Pages.bd.com/extended-genotyping.

About BD
BD is one of the world's largest global medical technology companies, advancing the world of health by improving medical discovery, diagnosis and care delivery. The company supports those on the front lines of healthcare by developing innovative technologies, services and solutions that help advance both clinical treatments for patients and clinical processes for healthcare providers. BD and its more than 70,000 employees make the care delivery process safer and more efficient for clinicians, enable laboratory scientists to accurately detect disease, and develop next-generation diagnostics and treatments. has a passion and commitment to improving the ability of researchers to develop With a presence in nearly every country, BD partners with organizations around the world to tackle some of the most challenging global health challenges. By working closely with our customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety and expand access to care. For more information about BD, visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter). @BDandCo or Instagram @becton_dickinson

^I Chua B et al. Int J Environ Res Public Health. 2021 4 26;18(9):4586.

ⁱⁱ Irvin, M. et al. (2018) Detecting cervical precancers and reaching under-tested women by using self-sample her HPV testing: An updated meta-analysis. Bmj 363, k4823; Cadman, L. et al. (2021) Randomized comparison of different vaginal self-sampling devices and urine for human papillomavirus testing – Predictors 5.1.Cancer epidemiol biomarker January 29, 2021; DOI: 10.1158/1055-9965.EPI-20-1226; Rohner, E. et al. (2020) Test accuracy for human papillomavirus in urine for the detection of cervical intraepithelial neoplasia. J Clin Microbiol 58 (3)

ⁱⁱⁱ https://www.who.int/news/item/17-11-2020-a-cervical-cancer-free-future-first-ever-global-commitment-to-eliminate-a-cancer

^iv https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

^v https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-ar-2021-web-report.pdf?sfvrsn=591fc02c_0

^V National Population Health Survey 2019, ISBN 978-981-14-5641-1.Ministry of Health, Health Promotion Committee, Epidemiology and Disease Control Division, Policy Research and Monitoring Group Singapore.

^vii https://www.cancer.org/cancer/risk-prevention/hpv/hpv-and-cancer-info.html

SOURCE BD (Becton, Dickinson & Company)